{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=lenalidomide&page=18", "query": { "intervention": "lenalidomide", "page": 18 }, "page_size": 10 }, "pagination": { "page": 18, "page_size": 10, "total_count": 703, "total_pages": 71, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=lenalidomide&page=19&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=lenalidomide&page=17&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-25T08:22:38.828Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00120120", "title": "Study to Evaluate the Efficacy and Safety of Lenalidomide in the Treatment of Painful Lumbar Radiculopathy", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Radiculopathy" ], "interventions": [ { "name": "Lenalidomide (CC-5013)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Celgene Corporation", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 181, "start_date": "2005-01", "completion_date": "2007-11", "has_results": false, "last_update_posted_date": "2009-09-23", "last_synced_at": "2026-10-25T08:22:38.828Z", "location_count": 23, "location_summary": "Phoenix, Arizona • Tucson, Arizona • Loma Linda, California + 20 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Loma Linda", "state": "California" }, { "city": "Palm Bay", "state": "Florida" }, { "city": "Weston", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT00120120" }, { "nct_id": "NCT06208150", "title": "A Study Comparing Talquetamab Plus Pomalidomide, Talquetamab Plus Teclistamab, and Elotuzumab, Pomalidomide, and Dexamethasone or Pomalidomide, Bortezomib, and Dexamethasone in Participants With Relapsed or Refractory Myeloma Who Have Received an Anti-CD38 Antibody and Lenalidomide", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Multiple Myeloma" ], "interventions": [ { "name": "Talquetamab", "type": "DRUG" }, { "name": "Pomalidomide", "type": "DRUG" }, { "name": "Teclistamab", "type": "DRUG" }, { "name": "Elotuzumab", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" }, { "name": "Bortezomib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Janssen Research & Development, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 838, "start_date": "2024-01-22", "completion_date": "2028-12-31", "has_results": false, "last_update_posted_date": "2026-09-25", "last_synced_at": "2026-10-25T08:22:38.828Z", "location_count": 49, "location_summary": "Clovis, California • Santa Monica, California • New Haven, Connecticut + 41 more", "locations": [ { "city": "Clovis", "state": "California" }, { "city": "Santa Monica", "state": "California" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Newark", "state": "Delaware" }, { "city": "Hollywood", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT06208150" }, { "nct_id": "NCT01615029", "title": "Daratumumab in Combination With Lenalidomide and Dexamethasone in Relapsed and Relapsed-refractory Multiple Myeloma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Multiple Myeloma" ], "interventions": [ { "name": "Part 1 (Dose Escalation): Daratumumab", "type": "DRUG" }, { "name": "Part 2 (Dose Expansion): Daratumumab", "type": "DRUG" }, { "name": "Lenalidomide", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Janssen Research & Development, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 45, "start_date": "2012-06-26", "completion_date": "2024-10-23", "has_results": true, "last_update_posted_date": "2026-03-16", "last_synced_at": "2026-10-25T08:22:38.828Z", "location_count": 1, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT01615029" }, { "nct_id": "NCT03652064", "title": "A Study Comparing Daratumumab, VELCADE (Bortezomib), Lenalidomide, and Dexamethasone (D-VRd) With VELCADE, Lenalidomide, and Dexamethasone (VRd) in Participants With Untreated Multiple Myeloma and for Whom Hematopoietic Stem Cell Transplant is Not Planned as Initial Therapy", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Multiple Myeloma" ], "interventions": [ { "name": "Daratumumab", "type": "DRUG" }, { "name": "Bortezomib", "type": "DRUG" }, { "name": "Lenalidomide", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Janssen Research & Development, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 395, "start_date": "2018-11-06", "completion_date": "2026-04-21", "has_results": true, "last_update_posted_date": "2026-06-02", "last_synced_at": "2026-10-25T08:22:38.828Z", "location_count": 19, "location_summary": "Cerritos, California • Jacksonville, Florida • Fort Wayne, Indiana + 15 more", "locations": [ { "city": "Cerritos", "state": "California" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Fort Wayne", "state": "Indiana" }, { "city": "Louisville", "state": "Kentucky" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT03652064" }, { "nct_id": "NCT01208051", "title": "Cediranib Maleate With or Without Lenalidomide for the Treatment of Thyroid Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Refractory Differentiated Thyroid Gland Carcinoma", "Refractory Thyroid Gland Follicular Carcinoma", "Refractory Thyroid Gland Hurthle Cell Carcinoma", "Refractory Thyroid Gland Papillary Carcinoma", "Unresectable Thyroid Gland Carcinoma" ], "interventions": [ { "name": "Cediranib", "type": "DRUG" }, { "name": "Cediranib Maleate", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Lenalidomide", "type": "DRUG" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 127, "start_date": "2010-09-09", "completion_date": "2020-02-01", "has_results": true, "last_update_posted_date": "2021-07-15", "last_synced_at": "2026-10-25T08:22:38.828Z", "location_count": 30, "location_summary": "Duarte, California • Los Angeles, California • Sacramento, California + 24 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "South Pasadena", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01208051" }, { "nct_id": "NCT00091624", "title": "A Study of Doxil, Vincristine and Decadron (DVd) +/ CC-5013 in Relapsed Refractory Multiple Myeloma (MM)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Multiple Myeloma" ], "interventions": [ { "name": "CC-5013", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Celgene Corporation", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 77, "start_date": "2003-03", "completion_date": "2007-09", "has_results": false, "last_update_posted_date": "2016-12-01", "last_synced_at": "2026-10-25T08:22:38.828Z", "location_count": 1, "location_summary": "Cleveland, Ohio", "locations": [ { "city": "Cleveland", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT00091624" }, { "nct_id": "NCT00179647", "title": "Expanded Access Program:Lenalidomide With or Without Dexamethasone In Previously Treated Subjects With Multiple Myeloma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Multiple Myeloma" ], "interventions": [ { "name": "lenalidomide", "type": "DRUG" }, { "name": "dexamethasone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Celgene Corporation", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1913, "start_date": "2005-09", "completion_date": "2009-04", "has_results": true, "last_update_posted_date": "2010-03-16", "last_synced_at": "2026-10-25T08:22:38.828Z", "location_count": 63, "location_summary": "Scottsdale, Arizona • Berkeley, California • La Jolla, California + 54 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Berkeley", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Diego", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00179647" }, { "nct_id": "NCT01301963", "title": "Filgrastim With or Without Plerixafor in Treating Patients With Multiple Myeloma Previously Treated With Lenalidomide", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Refractory Multiple Myeloma" ], "interventions": [ { "name": "plerixafor", "type": "DRUG" }, { "name": "filgrastim", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "Case Comprehensive Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "19 Years", "maximum_age": null, "sex": "ALL", "summary": "19 Years and older" }, "enrollment_count": 9, "start_date": "2011-07", "completion_date": null, "has_results": true, "last_update_posted_date": "2014-08-06", "last_synced_at": "2026-10-25T08:22:38.828Z", "location_count": 2, "location_summary": "Cleveland, Ohio", "locations": [ { "city": "Cleveland", "state": "Ohio" }, { "city": "Cleveland", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT01301963" }, { "nct_id": "NCT01075321", "title": "Everolimus and Lenalidomide in Treating Patients With Relapsed or Refractory Non-Hodgkin or Hodgkin Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Adult Nasal Type Extranodal NK/T-cell Lymphoma", "Anaplastic Large Cell Lymphoma", "Angioimmunoblastic T-cell Lymphoma", "Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue", "Hepatosplenic T-cell Lymphoma", "Nodal Marginal Zone B-cell Lymphoma", "Peripheral T-cell Lymphoma", "Post-transplant Lymphoproliferative Disorder", "Recurrent Adult Burkitt Lymphoma", "Recurrent Adult Diffuse Large Cell Lymphoma", "Recurrent Adult Hodgkin Lymphoma", "Recurrent Adult T-cell Leukemia/Lymphoma", "Recurrent Grade 1 Follicular Lymphoma", "Recurrent Grade 2 Follicular Lymphoma", "Recurrent Grade 3 Follicular Lymphoma", "Recurrent Mantle Cell Lymphoma", "Recurrent Mycosis Fungoides/Sezary Syndrome", "Splenic Marginal Zone Lymphoma", "Waldenstrom Macroglobulinemia" ], "interventions": [ { "name": "everolimus", "type": "DRUG" }, { "name": "lenalidomide", "type": "DRUG" }, { "name": "laboratory biomarker analysis", "type": "OTHER" }, { "name": "polymorphism analysis", "type": "GENETIC" }, { "name": "immunohistochemistry staining method", "type": "OTHER" }, { "name": "microarray analysis", "type": "GENETIC" }, { "name": "fluorescence in situ hybridization", "type": "GENETIC" } ], "intervention_types": [ "DRUG", "OTHER", "GENETIC" ], "sponsor": "Mayo Clinic", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 58, "start_date": "2011-01-10", "completion_date": "2020-02-13", "has_results": true, "last_update_posted_date": "2020-10-22", "last_synced_at": "2026-10-25T08:22:38.828Z", "location_count": 2, "location_summary": "Scottsdale, Arizona • Rochester, Minnesota", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT01075321" }, { "nct_id": "NCT04270409", "title": "Isatuximab in Combination With Lenalidomide and Dexamethasone in High-risk Smoldering Multiple Myeloma", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Plasma Cell Myeloma" ], "interventions": [ { "name": "Isatuximab SAR650984", "type": "DRUG" }, { "name": "Lenalidomide", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" }, { "name": "Montelukast or equivalent", "type": "DRUG" }, { "name": "Acetaminophen", "type": "DRUG" }, { "name": "Diphenhydramine or equivalent", "type": "DRUG" }, { "name": "Methylprednisolone or equivalent", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sanofi", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 337, "start_date": "2020-06-16", "completion_date": "2033-10-21", "has_results": false, "last_update_posted_date": "2025-12-12", "last_synced_at": "2026-10-25T08:22:38.828Z", "location_count": 9, "location_summary": "Los Angeles, California • Denver, Colorado • Jacksonville, Florida + 6 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Miami", "state": "Florida" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT04270409" } ] }